Dr. Frank Liu, CEO of Guangzhou DiQi Pharmaceuticals Co., Ltd, delivered a keynote speech at the inaugural Modified New Drug Trends and Technology Summit, sharing insights on formulation development and optimization for modified new drugs. He presented expertise in enhancing high-end formulations and modifying solid oral dosage forms, including the development journey of the company's injectable risperidone microspheres (4-week formulation), key quality control aspects of the critical excipient polylactic-co-glycolic acid (PLGA), a biodegradable material, and its application in modified sustained-release implants and long-acting injectable microspheres.

On May 11-12, 2021, Guangzhou DiQi Pharmaceuticals Co., Ltd participated in the Greater Bay Area (Guangzhou) Biomedical Innovators Summit. Dr. Frank Liu (CEO) of Guangzhou DiQi Pharmaceuticals Co., Ltd delivered a keynote speech on the application of biodegradable materials in Class II innovative drugs. The company also showcased its latest research achievements and samples, including poly(lactic-co-glycolic acid) (PLGA), long-acting implants, ocular implants, and sustained-release microspheres. These innovations garnered significant attention and interest from attendees, particularly those involved in technology and investment sectors. Many attendees expressed astonishment and admiration upon learning that DiQi's implant can be injected into the eyeball and sustain release for six months.

These new policies and initiatives not only affirm the importance of formulation technology—particularly high-end formulation technology—but also pave a fast-track path for the development and industrialization of high-end formulations. They have opened up vast opportunities for his “high-end formulation dream.” Recently, a reporter from Pharma Intelligence Media conducted an exclusive interview with Dr. Frank Liu, Chairman of Guangzhou DiQi Pharmaceuticals Co., Ltd. and a Guangzhou Innovation and Entrepreneurship Leading Talent.